semaglutide abbreviation Canada approves generic from Dr. Reddy's, a G7 first enabled by Novo Nordisk's lapsed CAD$250 patent Semaglutide 2.4 mg clinical outcomes

The same 2025 trial reports that long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial, "Patients on semaglutide experienced an average weight loss of 5.6 kg, compared to 2.3 kg with other treatments.", showing a measurable weight advantage that often drives secondary hormonal and quality of life effects

Semaglutide GLP-1 is intended for long-term use to facilitate meaningful and sustainable weight loss

But this could mean a potential clash: Kennedy is a vocal critic of the weight-loss drugs while Oz is an ardent advocate

Semaglutide has a larger linker molecule and an extended fatty acid derivative than Liraglutide